(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, provided an update on the expected timing of a U.S. FDA response to the protocol for its planned Phase 3 study of Efzofitimod in Pulmonary sarcoidosis.